BioSpace News Archive

Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures.

SHEPHERD Therapeutics, a company dedicated to catalyzing lifesaving treatments for cancer patients, is pleased to present an e-poster of results from a computational approach to optimizing therapeutic selection for cancer patients using the Company’s proprietary precision-oncology DELVE platform, at the European Society for Medical Oncology Virtual Congress 2021.

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, enrolled the first patient in SYMPHONY, a Phase 3, randomized, double-blind, placebo-controlled trial of AXS-12 in patients with narcolepsy.

Instil Bio, Inc. announced that a subset analysis of treatment outcomes with unselected autologous tumor infiltrating lymphocytes in patients with checkpoint inhibitor-refractory advanced cutaneous melanoma was presented at the 2021 European Society for Medical Oncology Congress, taking place virtually from September 16-21, 2021.

Guidewires are essential tools to track through a vessel and enable access and ability to cross the lesion with interventional devices.

The increasing rate of investment for R & D activities to develop and promote the services will boost growth opportunities in the human combination vaccines market.

BeyondSpring Pharmaceuticals, a global pharmaceutical company focused on the development of innovative cancer therapeutics, announced new positive data on plinabulin from its chemotherapy-induced neutropenia prevention program with three poster presentations at the European Society for Medical Oncology 2021 Congress taking place from September 16-21, 2021.

Rune Labs today announced a $22.8 million Series A financing.

Phio Pharmaceuticals Corp., a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform, announced results of a new study showing that local treatment in vivo with INTASYL can cure tumors and generate systemic tumor immunity that is both durable and tumor specific.

Gilead Sciences, Inc. announced new data from the Phase 3 ASCENT study of Trodelvy® in patients with relapsed or refractory metastatic triple-negative breast cancer who received two or more prior systemic therapies, at least one of them for metastatic disease.